Interleukin‐10‐Modulated Immature Dendritic Cells Control the Proinflammatory Environment in Multiple Sclerosis

Multiple sclerosis (MS) is a disabling, inflammatory, demyelinating disease of the central nervous system considered to be mediated by autoreactive T cells. Dendritic cells (DC), being professional antigen‐presenting cells, play a pivotal role in the decision between T‐cell activation and anergy. It has been suggested that mature DC (mDC) induce immunity, whereas immature DC (imDC) have the potential to induce tolerance. In this study, we investigated the effects of autologous imDC versus autologous mDC on lymphocytes with respect to the expression of functionally important cell‐surface molecules and production of cytokines. Our aims were to investigate whether the maturation status of DC differs between MS and healthy controls (HC) and to explore whether the effects of DC on T‐cell responses differ between MS and HC. DC were generated from adherent blood mononuclear cells from patients with MS and HC. imDC were obtained by culture with either granulocyte–macrophage colony‐stimulating factor (GM‐CSF) + interleukin‐4 (IL‐4) or GM‐CSF + IL‐4 + IL‐10. mDC were obtained by adding lipopolysaccharide to DC cultures. Upon coculture with autologous lymphocytes, mDC activated the autologous T cells as reflected by increased CD25 and cytotoxic T‐lymphocyte antigen‐4 expression on CD4+ T cells together with the increased production of both T helper 1 (Th1) (IL‐2 and interferon‐γ) and Th2 (IL‐10 and IL‐4) cytokines. Unmodulated naïve imDC induced the production of only IL‐4. An exposure of imDC to IL‐10 induced the production of IL‐4 as well as IL‐10 by autologous lymphocytes. We hypothesize that such imDC are important in controlling the proinflammatory environment in vivo in patients with MS.

[1]  E. Granieri,et al.  Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing–remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings , 2003, Journal of Neuroimmunology.

[2]  M. Kapsenberg,et al.  Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1 , 2003, The Journal of Immunology.

[3]  M. Duddy,et al.  CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions , 2003, Multiple sclerosis.

[4]  F. Fazekas,et al.  Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis , 2003, Journal of the Neurological Sciences.

[5]  A. Enk,et al.  Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.

[6]  Gerold Schuler,et al.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? , 2002, Trends in immunology.

[7]  R. de Waal Malefyt,et al.  The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). , 2002, Cytokine & growth factor reviews.

[8]  R. Steinman,et al.  Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. , 2002, Blood.

[9]  B. Xiao,et al.  Dendritic cells exposed in vitro to TGF‐β1 ameliorate experimental autoimmune myasthenia gravis , 2002, Clinical and experimental immunology.

[10]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[11]  H. Link,et al.  Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN‐β and IL‐10 , 2001, Clinical and experimental immunology.

[12]  Giampiero Girolomoni,et al.  Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions1 , 2001, The Journal of Immunology.

[13]  H. Link,et al.  Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis , 2001, Journal of Neuroimmunology.

[14]  Nina Bhardwaj,et al.  Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[15]  A. Enk,et al.  Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells , 2000, The Journal of experimental medicine.

[16]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[17]  G. Schuler,et al.  Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation , 1999, FEBS letters.

[18]  M. Foti,et al.  Early events in dendritic cell maturation induced by LPS. , 1999, Microbes and infection.

[19]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[20]  K. Palucka,et al.  Dendritic cells as the terminal stage of monocyte differentiation. , 1998, Journal of immunology.

[21]  A. Enk,et al.  Induction of tolerance by IL-10-treated dendritic cells. , 1997, Journal of immunology.

[22]  V. Verhasselt,et al.  Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin‐10 , 1997, European journal of immunology.

[23]  M. Goldman,et al.  Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells , 1995, European journal of immunology.

[24]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.